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Editorial on the Research Topic
Insights Into Biomarkers, Cytokines, and Chemokines in Skin Cancer
As our understanding of immune system involvement in skin cancer has increased, so has the
development of immunotherapies to target aggressive, un-resectable, or metastatic skin cancers,
resulting in significant improvements in survival for previously untreatable patients. However,
the high rate of non-responders and the development of resistance to immunotherapy over time
highlights the need to improve the efficacy of these treatments. The skin microenvironment
is unlike other non-lymphoid organs in so far as lymphocytes constantly traffic to and from
the skin and immune surveillance occurs even in the absence of infection (Lafouresse and
Groom). Thus, the immune system plays a critical role in the maintenance of a healthy skin
microenvironment, and disruption of immune surveillance mechanisms is thought to contribute to
multiple skin neoplasia’s, including cancer. Our current Research Topic highlights the complexity
of the relationship between the skin, immune system and skin cancer, and underlines the need
to characterize the specific molecular mechanisms involved in cell trafficking in a context-specific
manner. Here we provide a brief overview of the five review articles and two original research
papers that contributed to our recent Research Topic, focusing on general ideas that have emerged
and implications for future research in the field.
Amajor theme running through this topic is the dissection ofmolecularmechanisms involved in
lymphocyte trafficking into the skin and tumors, with a particular focus on the specific chemokines
involved (Lafouresse and Groom; Yam and Chtanova; Kuo et al.). Trafficking of immune cells
into the skin is a complex and highly regulated process as each cell type responds to a specific
set of signals, and chemokines and their receptors can be variably expressed by both normal
skin cells and malignant cells. In the review by Kuo et al., the role of the chemokine receptor
CXCR3 and associated ligands in interferon-induced inflammatory responses and skin cancer
is examined in detail, and describes how CXCR3 expression on immune cells often promotes
anti-tumor responses, while conversely, expression on tumor cells can lead to metastasis. Evidence
for the opposing roles of immune cells in cancer progression and metastasis is further described
in the mini review by Yam and Chtanova, in which the roles of other chemokine receptors and
ligands in the trafficking of dendritic cells, macrophages, neutrophils and natural killer cells into
tumors is examined. In addition to the movement of lymphocytes, Ju et al. further address the
pathways involved in metastasic spread, with chemokines and their receptors remaining a key
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focus. Importantly, the authors discuss the concept that the
mechanisms behind metastatic spread may also enhance tumor
cell survival, making these pathways attractive targets for
future therapies.
Tumors that are rich in cytotoxic T cells tend to be associated
with a better prognosis and response to immunotherapy
(Lafouresse and Groom; Yam and Chtanova). However, the role
of innate immune cells including dendritic cells, macrophages,
neutrophils, and natural killer cells in tumors is more complex, as
they can mediate anti-tumor responses through the recruitment
of cytotoxic T cells, or alternatively may inhibit anti-tumor
responses through expression of suppressive factors, resulting
in enhanced tumor growth (Yam and Chtanova). Even when T
cells are effectively recruited to tumors, they may be inhibited
by exhaustion or infiltration of suppressive T regulatory cells
(Lafouresse and Groom). A greater understanding of the
interplay between innate and adaptive lymphocytes, and how this
ultimately influences cancer growth, is needed to promote greater
response rates to immunotherapy, which is the second major
theme of our Research Topic. The articles presented emphasize
the urgent need to understand the specific mechanisms behind
non-response or developed resistance to emerging treatments.
To improve responses and treatment regimes, biomarkers
and new predictors for treatment response are urgently needed
(Bridge et al.). In their review, Bridge et al. examined
current research into checkpoint inhibitor therapy for various
skin cancers and the advances that have been made in
identifying biomarkers for non-response, tolerance, and toxicity.
The authors discuss the current state of immunotherapy for
metastatic skin cancers, the limitations of the current biomarkers,
and address important questions pertaining to the general
unpredictability of the responses to checkpoint inhibitor (CPI)
therapies, such as: Can CPIs be re-administered in the case of
relapse? Do all CPI treatments work through the same pathways,
meaning patients who are resistant to one would be resistant
to others? And when should treatment be stopped? These
questions reflect some of the current priorities for improving
immunotherapy outcomes.
T cell exhaustion, whereby T cells progressively lose their
effector function, presents a major challenge to effective
immunotherapies. An original study by Graves et al. analyzed the
expression of inhibitory markers on the surface of T cells from
16 patients treated with Pembrolizumab, an anti-PD-1 therapy
for metastatic melanoma. They identified upregulation of PD-1
and TIM-3 on CD8T cells as potential biomarkers to identify
non-responders to Pembrolizumab therapy. The second original
research paper presented as part of this topic also details a search
for biomarkers, this time for squamous cell carcinoma (SCC).
Crawford et al. identified two anthrax toxin receptors, Tumor
Endothelial Marker 8 (TEM8) and Capillary Morphogenesis
Gene 2 (CMG2), that are upregulated on SCC cells. Protective
antigen (PA), a protein from Bacillus anthracis that has been
shown to bind to these receptors, was fluorescently labeled and
intravenously infused in a mouse model of SCC. The authors
showed that they were able to detect tumor-specific uptake
of PA through binding with TEM8. This research identifying
TEM8 as a potential biomarker for SCC has important
implications for treatment, as it could facilitate early, accurate
detection of skin malignancy and enhance surgical precision of
tumor removal.
The studies in this issue illustrate the complexities and
challenges researchers face in designing effective and long-lasting
immunotherapies for skin cancer. Through detailed studies,
such as those presented here, it may well become possible to
harness the immune system to destroy skin cancer and prevent
its recurrence. Characterization of immune cell movements and
functions within the skin and in response to immunotherapies
are a priority in order to provide the best possible treatment for
patients in the future.
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